With a Food and Drug Administration decision on Biogen’s Alzheimer’s drug due on June 7, patients on the treatment worry it will be rejected. If approved, aducanumab would be the first treatment for mild cognitive impairment or dementia caused by Alzheimer’s. (The Washington Post)

Top Journal of the American Medical Association editor Dr. Howard Bauchner is stepping down from his role after a colleague made controversial comments about racism during a podcast. Dr. Edward Livingston, another editor at the journal, dismissed the idea of structural racism in healthcare. (The New York Times)

Amgen will pay $400 million for Kyowa Kirin’s antibody that aims to treat moderate to severe atopic dermatitis. The drug is a potential first-in-class and best-in-class product about to enter a Phase III trial. (Endpoints News)

Companies are aiming to boost vaccination rates by offering incentives from free donuts to million-dollar prizes. Some experts say incentives of this sort may become increasingly important in convincing hesitant Americans to receive the shot. (CNBC Weekly)

Four global agencies are calling for wealthy nations to invest up to $50 billion in vaccine manufacturing capacity around the world. The extra funding could help boost the goal of vaccinating 30% of the population of low- and middle-income countries to 40% by the first months of 2022. (STAT)